查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
人类绒毛膜促性腺激素的全球市场 - 成长，未来展望，竞争分析(2022年～2030年)
市场调查报告书
商品编码
1180651

人类绒毛膜促性腺激素的全球市场 - 成长，未来展望，竞争分析(2022年～2030年)

Human Chorionic Gonadotropin Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030
出版日期: | 出版商: Acute Market Reports | 英文 115 Pages | 商品交期: 最快1-2个工作天内

价格

全球人类绒毛膜促性腺激素的市场规模，从2022年到2030年预计显示7.5％的指数函数增加率。北美，预计成为人类绒毛膜促性腺激素的最大且最潜在的地区市场。不孕症的发生率上升，生活方式的影响等，男性与女性的荷尔蒙功能不全，是促进全球人类绒毛膜促性腺激素市场成长的主要促进因素。还有亚太地区，预计至2030年成为在人类绒毛膜促性腺激素市场中最具潜力的地区市场。由于潜在经济形势的发展，可支配所得增加，不孕治疗相关的国民意识高涨，政府提供有利政策的辅助强化等许多要素，预计促进亚太地区市场成长。

本报告提供全球人类绒毛膜促性腺激素市场相关调查，市场趋势，竞争资讯，市场区隔分析，新兴趋势，技术分析，企业简介等资讯。

目录

第1章 序文

  • 报告概要
  • 市场区隔
  • 调查手法

第2章 摘要整理

  • 市场概述:全球人类绒毛膜促性腺激素市场
  • 全球人类绒毛膜促性腺激素市场:各治疗(2021年)
  • 全球人类绒毛膜促性腺激素市场:各技术(2021年)
  • 全球人类绒毛膜促性腺激素市场:各地区(2021年)
  • 富有魅力的投资提案:各地区(2021年)

第3章 人类绒毛膜促性腺激素市场:竞争分析

  • 主要的人类绒毛膜促性腺激素市场供应商的市场定位
  • 人类绒毛膜促性腺激素市场供应商的采用策略
  • 主要的产业策略
  • 阶层分析:2021年对2030年

第4章 人类绒毛膜促性腺激素市场:常量分析和市场动态

  • 简介
  • 全球人类绒毛膜促性腺激素市场金额(2020年～2030年)
  • 市场动态
    • 推动市场要素
    • 阻碍市场要素
    • 主要课题
    • 主要的机会
  • 促进因素与阻碍因素的影响分析
  • See-Saw分析

第5章 人类绒毛膜促性腺激素市场:各治疗(2020年～2030年)

  • 市场概要
  • 成长和收益分析:2021年对2030年
  • 市场区隔
    • 女性不孕治疗
    • 精子减少症治疗
    • 停留精巢治疗
    • 其他

第6章 人类绒毛膜促性腺激素市场:各技术(2020年～2030年)

  • 市场概要
  • 成长和收益分析:2021年对2030年
  • 市场区隔
    • 天然物来源提取
    • 重组DNA技术

第7章 北美的人类绒毛膜促性腺激素市场(2020年～2030年)

  • 市场概要
  • 人类绒毛膜促性腺激素市场:各治疗(2020年～2030年)
  • 人类绒毛膜促性腺激素市场:各技术(2020年～2030年)
  • 人类绒毛膜促性腺激素市场:各地区(2020年～2030年)
    • 北美

第8章 英国、欧洲联盟的人类绒毛膜促性腺激素市场(2020年～2030年)

  • 市场概要
  • 人类绒毛膜促性腺激素市场:各治疗(2020年～2030年)
  • 人类绒毛膜促性腺激素市场:各技术(2020年～2030年)
  • 人类绒毛膜促性腺激素市场:各地区(2020年～2030年)
    • 英国、欧洲联盟

第9章 亚太地区的人类绒毛膜促性腺激素市场(2020年～2030年)

  • 市场概要
  • 人类绒毛膜促性腺激素市场:各治疗(2020年～2030年)
  • 人类绒毛膜促性腺激素市场:各技术(2020年～2030年)
  • 人类绒毛膜促性腺激素市场:各地区(2020年～2030年)
    • 亚太地区

第10章 南美的人类绒毛膜促性腺激素市场(2020年～2030年)

  • 市场概要
  • 人类绒毛膜促性腺激素市场:各治疗(2020年～2030年)
  • 人类绒毛膜促性腺激素市场:各技术(2020年～2030年)
  • 人类绒毛膜促性腺激素市场:各地区(2020年～2030年)
    • 南美

第11章 中东、非洲的人类绒毛膜促性腺激素市场(2020年～2030年)

  • 市场概要
  • 人类绒毛膜促性腺激素市场:各治疗(2020年～2030年)
  • 人类绒毛膜促性腺激素市场:各技术(2020年～2030年)
  • 人类绒毛膜促性腺激素市场:各地区(2020年～2030年)
    • 中东、非洲

第12章 企业简介

  • Ferring B.V.
  • Bristol-Myers Squibb Company
  • EMD Serono, Inc.
  • Fresenius Kabi USA, LLC
  • Merck & Co., Inc.
Product Code: 136987-08-22

Global Human Chorionic Gonadotropin Market is having an exponential growth rate of 7.5% from 2022 to 2030.

Fertility patterns worldwide have changed dramatically and a rise in infertility rates have been observed since the last two decades. Even though newer assisted techniques such as in-vitro fertilization have been well developed, still fertility drugs are the first choice for treatment of infertility issues. Even in the fertility drugs category, hormonal products are preferred the most. Since the human body is governed by hormones, infertility is considered to be caused due to the abnormal play of the hormones.

Human chorionic gonadotropin (HCG) is available in two forms. One is a powder derived from the urine of pregnant women which needs to be dissolved in sterile water, loaded into a syringe, and injected into a muscle. Ovidrel is another more expensive but more convenient product produced by recombinant technology, pre-packaged into a syringe for injection with a short needle. HCG is used in some patients who are usually receiving other fertility drugs in order to trigger ovulation. The eggs are released from their follicles about 40 hours after the HCG injection. Artificial insemination will usually be scheduled for 36-44 hours after the HCG injection when a single insemination is planned or at approximately 24 and 48 hours after the HCG injection when two inseminations are to be done.

Two main regimens of gonadotropin ovarian stimulation are used, namely step-up and the step-down protocols. The choice of gonadotropin preparation and treatment regimen depends on the underlying ovarian dysfunction. Strict monitoring of gonadotropin treatment with implementation of strict cancellation criteria are recommended to minimize the risks of ovarian hyperstimulation and multiple pregnancy.

Oligospermia supported the demand for HCG drugs in the market

For the purpose of this study, the global human chorionic gonadotropin market is represented by key therapeutic areas such as female infertility treatment, oligospermia, cryptorchidism and others. Several factors such as growing incidence of infertility in women, contributed by increased maternity age, lifestyle effects and others, hormonal dysfunctions in men and growing incidence of oligospermia are the key factors that have supported the demand for HCG drugs in the market.

Recombinant HCG is Key driving factor

For the purpose of this report, the technology segment of the global human chorionic gonadotropin market has been segmented into natural source extract and recombinant DNA technology. Urine-derived HCG has been a chief treatment source for various hormonal conditions. However in view of purity-related issues, HCG manufacturing through recombinant production technology. Equal efficacy or recombinant HCG along with added safety as against natural source HCG are the key driving factors that lead to higher demand for recombinant HCG in the global market.

Asia-Pacific is expected to be the most potential regional market

North America is expected to be the largest and most potential regional market for human chorionic gonadotropin. North America constitutes regional markets of U.S. and Canada, the rising incidence of infertility cases, lifestyle effects, and others, hormonal dysfunctions in men and women are the major driver for the growth of the global human chorionic gonadotropin market. Asia-Pacific is expected to be the most potential regional market for human chorionic gonadotropin market by 2030. Over the next six years, the growth of the market in the Asia-Pacific region is likely to be centered in Japan, South Korea, China, and India. Numerous factors such as developing economical landscape, increasing disposable incomes, growing public awareness related to infertility therapy, and increasing government support through providing favorable policies are the major factors expected to assist the growth of Asia-Pacific market.

Market Players

The leading key players in human chorionic gonadotropin market are EMD Serono, Inc., Ferring B.V., Merck & Co., Inc., Bristol Myers Squibb Company and Fresenius Kabi USA, LLC.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Human Chorionic Gonadotropin market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Human Chorionic Gonadotropin market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Treatment

Female Infertility Treatment

Oligospermia Treatment

Cryptorchidism Treatment

Others

Technology

Natural Source Extraction

Recombinant DNA Technology

Region Segment (2020-2030; US$ Million)

North America

U.S.

Canada

Rest of North America

UK and European Union

UK

Germany

Spain

Italy

France

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East and Africa

GCC

Africa

Rest of Middle East and Africa

Global Impact of COVID-19 Segment (2020-2021; US$ Million )

Pre COVID-19 situation

Post COVID-19 situation

Key questions answered in this report:

What are the key micro and macro environmental factors that are impacting the growth of Human Chorionic Gonadotropin market?

What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?

Estimated forecast and market projections up to 2030.

Which segment accounts for the fastest CAGR during the forecast period?

Which market segment holds a larger market share and why?

Are low and middle-income economies investing in the Human Chorionic Gonadotropin market?

Which is the largest regional market for Human Chorionic Gonadotropin market?

What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?

Which are the key trends driving Human Chorionic Gonadotropin market growth?

Who are the key competitors and what are their key strategies to enhance their market presence in the Human Chorionic Gonadotropin market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Human Chorionic Gonadotropin Market
  • 2.2. Global Human Chorionic Gonadotropin Market, By Treatment, 2021 (US$ Million)
  • 2.3. Global Human Chorionic Gonadotropin Market, By Technology, 2021 (US$ Million)
  • 2.4. Global Human Chorionic Gonadotropin Market, By Geography, 2021 (US$ Million)
  • 2.5. Attractive Investment Proposition by Geography, 2021

3. Human Chorionic Gonadotropin Market: Competitive Analysis

  • 3.1. Market Positioning of Key Human Chorionic Gonadotropin Market Vendors
  • 3.2. Strategies Adopted by Human Chorionic Gonadotropin Market Vendors
  • 3.3. Key Industry Strategies
  • 3.4. Tier Analysis 2021 Versus 2030

4. Human Chorionic Gonadotropin Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Human Chorionic Gonadotropin Market Value, 2020 - 2030, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis

5. Human Chorionic Gonadotropin Market: By Treatment, 2020-2030, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 5.3. Market Segmentation
    • 5.3.1. Female Infertility Treatment
    • 5.3.2. Oligospermia Treatment
    • 5.3.3. Cryptorchidism Treatment
    • 5.3.4. Others

6. Human Chorionic Gonadotropin Market: By Technology, 2020-2030, USD (Million)

  • 6.1. Market Overview
  • 6.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 6.3. Market Segmentation
    • 6.3.1. Natural Source Extraction
    • 6.3.2. Recombinant DNA Technology

7. North America Human Chorionic Gonadotropin Market, 2020-2030, USD (Million)

  • 7.1. Market Overview
  • 7.2. Human Chorionic Gonadotropin Market: By Treatment, 2020-2030, USD (Million)
  • 7.3. Human Chorionic Gonadotropin Market: By Technology, 2020-2030, USD (Million)
  • 7.4.Human Chorionic Gonadotropin Market: By Region, 2020-2030, USD (Million)
    • 7.4.1.North America
      • 7.4.1.1. U.S.
        • 7.4.1.1.1. Human Chorionic Gonadotropin Market: By Treatment, 2020-2030, USD (Million)
        • 7.4.1.1.1. Human Chorionic Gonadotropin Market: By Technology, 2020-2030, USD (Million)
      • 7.4.1.2. Canada
        • 7.4.1.2.1. Human Chorionic Gonadotropin Market: By Treatment, 2020-2030, USD (Million)
        • 7.4.1.2.1. Human Chorionic Gonadotropin Market: By Technology, 2020-2030, USD (Million)
      • 7.4.1.3. Rest of North America
        • 7.4.1.3.1. Human Chorionic Gonadotropin Market: By Treatment, 2020-2030, USD (Million)
        • 7.4.1.3.1. Human Chorionic Gonadotropin Market: By Technology, 2020-2030, USD (Million)

8. UK and European Union Human Chorionic Gonadotropin Market, 2020-2030, USD (Million)

  • 8.1. Market Overview
  • 8.2. Human Chorionic Gonadotropin Market: By Treatment, 2020-2030, USD (Million)
  • 8.3. Human Chorionic Gonadotropin Market: By Technology, 2020-2030, USD (Million)
  • 8.4.Human Chorionic Gonadotropin Market: By Region, 2020-2030, USD (Million)
    • 8.4.1.UK and European Union
      • 8.4.1.1. UK
        • 8.4.1.1.1. Human Chorionic Gonadotropin Market: By Treatment, 2020-2030, USD (Million)
        • 8.4.1.1.1. Human Chorionic Gonadotropin Market: By Technology, 2020-2030, USD (Million)
      • 8.4.1.2. Germany
        • 8.4.1.2.1. Human Chorionic Gonadotropin Market: By Treatment, 2020-2030, USD (Million)
        • 8.4.1.2.1. Human Chorionic Gonadotropin Market: By Technology, 2020-2030, USD (Million)
      • 8.4.1.3. Spain
        • 8.4.1.3.1. Human Chorionic Gonadotropin Market: By Treatment, 2020-2030, USD (Million)
        • 8.4.1.3.1. Human Chorionic Gonadotropin Market: By Technology, 2020-2030, USD (Million)
      • 8.4.1.4. Italy
        • 8.4.1.4.1. Human Chorionic Gonadotropin Market: By Treatment, 2020-2030, USD (Million)
        • 8.4.1.4.1. Human Chorionic Gonadotropin Market: By Technology, 2020-2030, USD (Million)
      • 8.4.1.5. France
        • 8.4.1.5.1. Human Chorionic Gonadotropin Market: By Treatment, 2020-2030, USD (Million)
        • 8.4.1.5.1. Human Chorionic Gonadotropin Market: By Technology, 2020-2030, USD (Million)
      • 8.4.1.6. Rest of Europe
        • 8.4.1.6.1. Human Chorionic Gonadotropin Market: By Treatment, 2020-2030, USD (Million)
        • 8.4.1.6.1. Human Chorionic Gonadotropin Market: By Technology, 2020-2030, USD (Million)

9. Asia Pacific Human Chorionic Gonadotropin Market, 2020-2030, USD (Million)

  • 9.1. Market Overview
  • 9.2. Human Chorionic Gonadotropin Market: By Treatment, 2020-2030, USD (Million)
  • 9.3. Human Chorionic Gonadotropin Market: By Technology, 2020-2030, USD (Million)
  • 9.4.Human Chorionic Gonadotropin Market: By Region, 2020-2030, USD (Million)
    • 9.4.1.Asia Pacific
      • 9.4.1.1. China
        • 9.4.1.1.1. Human Chorionic Gonadotropin Market: By Treatment, 2020-2030, USD (Million)
        • 9.4.1.1.1. Human Chorionic Gonadotropin Market: By Technology, 2020-2030, USD (Million)
      • 9.4.1.2. Japan
        • 9.4.1.2.1. Human Chorionic Gonadotropin Market: By Treatment, 2020-2030, USD (Million)
        • 9.4.1.2.1. Human Chorionic Gonadotropin Market: By Technology, 2020-2030, USD (Million)
      • 9.4.1.3. India
        • 9.4.1.3.1. Human Chorionic Gonadotropin Market: By Treatment, 2020-2030, USD (Million)
        • 9.4.1.3.1. Human Chorionic Gonadotropin Market: By Technology, 2020-2030, USD (Million)
      • 9.4.1.4. Australia
        • 9.4.1.4.1. Human Chorionic Gonadotropin Market: By Treatment, 2020-2030, USD (Million)
        • 9.4.1.4.1. Human Chorionic Gonadotropin Market: By Technology, 2020-2030, USD (Million)
      • 9.4.1.5. South Korea
        • 9.4.1.5.1. Human Chorionic Gonadotropin Market: By Treatment, 2020-2030, USD (Million)
        • 9.4.1.5.1. Human Chorionic Gonadotropin Market: By Technology, 2020-2030, USD (Million)
      • 9.4.1.6. Rest of Asia Pacific
        • 9.4.1.6.1. Human Chorionic Gonadotropin Market: By Treatment, 2020-2030, USD (Million)
        • 9.4.1.6.1. Human Chorionic Gonadotropin Market: By Technology, 2020-2030, USD (Million)

10. Latin America Human Chorionic Gonadotropin Market, 2020-2030, USD (Million)

  • 10.1. Market Overview
  • 10.2. Human Chorionic Gonadotropin Market: By Treatment, 2020-2030, USD (Million)
  • 10.3. Human Chorionic Gonadotropin Market: By Technology, 2020-2030, USD (Million)
  • 10.4.Human Chorionic Gonadotropin Market: By Region, 2020-2030, USD (Million)
    • 10.4.1.Latin America
      • 10.4.1.1. Brazil
        • 10.4.1.1.1. Human Chorionic Gonadotropin Market: By Treatment, 2020-2030, USD (Million)
        • 10.4.1.1.1. Human Chorionic Gonadotropin Market: By Technology, 2020-2030, USD (Million)
      • 10.4.1.2. Mexico
        • 10.4.1.2.1. Human Chorionic Gonadotropin Market: By Treatment, 2020-2030, USD (Million)
        • 10.4.1.2.1. Human Chorionic Gonadotropin Market: By Technology, 2020-2030, USD (Million)
      • 10.4.1.3. Rest of Latin America
        • 10.4.1.3.1. Human Chorionic Gonadotropin Market: By Treatment, 2020-2030, USD (Million)
        • 10.4.1.3.1. Human Chorionic Gonadotropin Market: By Technology, 2020-2030, USD (Million)

11. Middle East and Africa Human Chorionic Gonadotropin Market, 2020-2030, USD (Million)

  • 11.1. Market Overview
  • 11.2. Human Chorionic Gonadotropin Market: By Treatment, 2020-2030, USD (Million)
  • 11.3. Human Chorionic Gonadotropin Market: By Technology, 2020-2030, USD (Million)
  • 11.4.Human Chorionic Gonadotropin Market: By Region, 2020-2030, USD (Million)
    • 11.4.1.Middle East and Africa
      • 11.4.1.1. GCC
        • 11.4.1.1.1. Human Chorionic Gonadotropin Market: By Treatment, 2020-2030, USD (Million)
        • 11.4.1.1.1. Human Chorionic Gonadotropin Market: By Technology, 2020-2030, USD (Million)
      • 11.4.1.2. Africa
        • 11.4.1.2.1. Human Chorionic Gonadotropin Market: By Treatment, 2020-2030, USD (Million)
        • 11.4.1.2.1. Human Chorionic Gonadotropin Market: By Technology, 2020-2030, USD (Million)
      • 11.4.1.3. Rest of Middle East and Africa
        • 11.4.1.3.1. Human Chorionic Gonadotropin Market: By Treatment, 2020-2030, USD (Million)
        • 11.4.1.3.1. Human Chorionic Gonadotropin Market: By Technology, 2020-2030, USD (Million)

12. Company Profile

  • 12.1. Ferring B.V.
    • 12.1.1. Company Overview
    • 12.1.2. Financial Performance
    • 12.1.3. Product Portfolio
    • 12.1.4. Strategic Initiatives
  • 12.2. Bristol-Myers Squibb Company
    • 12.2.1. Company Overview
    • 12.2.2. Financial Performance
    • 12.2.3. Product Portfolio
    • 12.2.4. Strategic Initiatives
  • 12.3. EMD Serono, Inc.
    • 12.3.1. Company Overview
    • 12.3.2. Financial Performance
    • 12.3.3. Product Portfolio
    • 12.3.4. Strategic Initiatives
  • 12.4. Fresenius Kabi USA, LLC
    • 12.4.1. Company Overview
    • 12.4.2. Financial Performance
    • 12.4.3. Product Portfolio
    • 12.4.4. Strategic Initiatives
  • 12.5. Merck & Co., Inc.
    • 12.5.1. Company Overview
    • 12.5.2. Financial Performance
    • 12.5.3. Product Portfolio
    • 12.5.4. Strategic Initiatives

List of Tables

  • TABLE 1 Global Human Chorionic Gonadotropin Market By Treatment, 2020-2030, USD (Million)
  • TABLE 2 Global Human Chorionic Gonadotropin Market By Technology, 2020-2030, USD (Million)
  • TABLE 3 North America Human Chorionic Gonadotropin Market By Treatment, 2020-2030, USD (Million)
  • TABLE 4 North America Human Chorionic Gonadotropin Market By Technology, 2020-2030, USD (Million)
  • TABLE 5 U.S. Human Chorionic Gonadotropin Market By Treatment, 2020-2030, USD (Million)
  • TABLE 6 U.S. Human Chorionic Gonadotropin Market By Technology, 2020-2030, USD (Million)
  • TABLE 7 Canada Human Chorionic Gonadotropin Market By Treatment, 2020-2030, USD (Million)
  • TABLE 8 Canada Human Chorionic Gonadotropin Market By Technology, 2020-2030, USD (Million)
  • TABLE 9 Rest of North America Human Chorionic Gonadotropin Market By Treatment, 2020-2030, USD (Million)
  • TABLE 10 Rest of North America Human Chorionic Gonadotropin Market By Technology, 2020-2030, USD (Million)
  • TABLE 11 UK and European Union Human Chorionic Gonadotropin Market By Treatment, 2020-2030, USD (Million)
  • TABLE 12 UK and European Union Human Chorionic Gonadotropin Market By Technology, 2020-2030, USD (Million)
  • TABLE 13 UK Human Chorionic Gonadotropin Market By Treatment, 2020-2030, USD (Million)
  • TABLE 14 UK Human Chorionic Gonadotropin Market By Technology, 2020-2030, USD (Million)
  • TABLE 15 Germany Human Chorionic Gonadotropin Market By Treatment, 2020-2030, USD (Million)
  • TABLE 16 Germany Human Chorionic Gonadotropin Market By Technology, 2020-2030, USD (Million)
  • TABLE 17 Spain Human Chorionic Gonadotropin Market By Treatment, 2020-2030, USD (Million)
  • TABLE 18 Spain Human Chorionic Gonadotropin Market By Technology, 2020-2030, USD (Million)
  • TABLE 19 Italy Human Chorionic Gonadotropin Market By Treatment, 2020-2030, USD (Million)
  • TABLE 20 Italy Human Chorionic Gonadotropin Market By Technology, 2020-2030, USD (Million)
  • TABLE 21 France Human Chorionic Gonadotropin Market By Treatment, 2020-2030, USD (Million)
  • TABLE 22 France Human Chorionic Gonadotropin Market By Technology, 2020-2030, USD (Million)
  • TABLE 23 Rest of Europe Human Chorionic Gonadotropin Market By Treatment, 2020-2030, USD (Million)
  • TABLE 24 Rest of Europe Human Chorionic Gonadotropin Market By Technology, 2020-2030, USD (Million)
  • TABLE 25 Asia Human Chorionic Gonadotropin Market By Treatment, 2020-2030, USD (Million)
  • TABLE 26 Asia Human Chorionic Gonadotropin Market By Technology, 2020-2030, USD (Million)
  • TABLE 27 China Human Chorionic Gonadotropin Market By Treatment, 2020-2030, USD (Million)
  • TABLE 28 China Human Chorionic Gonadotropin Market By Technology, 2020-2030, USD (Million)
  • TABLE 29 Japan Human Chorionic Gonadotropin Market By Treatment, 2020-2030, USD (Million)
  • TABLE 30 Japan Human Chorionic Gonadotropin Market By Technology, 2020-2030, USD (Million)
  • TABLE 31 India Human Chorionic Gonadotropin Market By Treatment, 2020-2030, USD (Million)
  • TABLE 32 India Human Chorionic Gonadotropin Market By Technology, 2020-2030, USD (Million)
  • TABLE 33 Australia Human Chorionic Gonadotropin Market By Treatment, 2020-2030, USD (Million)
  • TABLE 34 Australia Human Chorionic Gonadotropin Market By Technology, 2020-2030, USD (Million)
  • TABLE 35 South Korea Human Chorionic Gonadotropin Market By Treatment, 2020-2030, USD (Million)
  • TABLE 36 South Korea Human Chorionic Gonadotropin Market By Technology, 2020-2030, USD (Million)
  • TABLE 37 Latin America Human Chorionic Gonadotropin Market By Treatment, 2020-2030, USD (Million)
  • TABLE 38 Latin America Human Chorionic Gonadotropin Market By Technology, 2020-2030, USD (Million)
  • TABLE 39 Brazil Human Chorionic Gonadotropin Market By Treatment, 2020-2030, USD (Million)
  • TABLE 40 Brazil Human Chorionic Gonadotropin Market By Technology, 2020-2030, USD (Million)
  • TABLE 41 Mexico Human Chorionic Gonadotropin Market By Treatment, 2020-2030, USD (Million)
  • TABLE 42 Mexico Human Chorionic Gonadotropin Market By Technology, 2020-2030, USD (Million)
  • TABLE 43 Rest of Latin America Human Chorionic Gonadotropin Market By Treatment, 2020-2030, USD (Million)
  • TABLE 44 Rest of Latin America Human Chorionic Gonadotropin Market By Technology, 2020-2030, USD (Million)
  • TABLE 45 Middle East and Africa Human Chorionic Gonadotropin Market By Treatment, 2020-2030, USD (Million)
  • TABLE 46 Middle East and Africa Human Chorionic Gonadotropin Market By Technology, 2020-2030, USD (Million)
  • TABLE 47 GCC Human Chorionic Gonadotropin Market By Treatment, 2020-2030, USD (Million)
  • TABLE 48 GCC Human Chorionic Gonadotropin Market By Technology, 2020-2030, USD (Million)
  • TABLE 49 Africa Human Chorionic Gonadotropin Market By Treatment, 2020-2030, USD (Million)
  • TABLE 50 Africa Human Chorionic Gonadotropin Market By Technology, 2020-2030, USD (Million)
  • TABLE 51 Rest of Middle East and Africa Human Chorionic Gonadotropin Market By Treatment, 2020-2030, USD (Million)
  • TABLE 52 Rest of Middle East and Africa Human Chorionic Gonadotropin Market By Technology, 2020-2030, USD (Million)

List of Figures

  • FIG. 1 Global Human Chorionic Gonadotropin Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Human Chorionic Gonadotropin Market: Quality Assurance
  • FIG. 5 Global Human Chorionic Gonadotropin Market, By Treatment, 2021
  • FIG. 6 Global Human Chorionic Gonadotropin Market, By Technology, 2021
  • FIG. 7 Global Human Chorionic Gonadotropin Market, By Geography, 2021
  • FIG. 8 Market Geographical Opportunity Matrix - Global Human Chorionic Gonadotropin Market, 2021
  • FIG. 9 Market Positioning of Key Human Chorionic Gonadotropin Market Players, 2021
  • FIG. 10 Global Human Chorionic Gonadotropin Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
  • FIG. 11 Global Human Chorionic Gonadotropin Market, By Treatment, 2021 Vs 2030, %
  • FIG. 12 Global Human Chorionic Gonadotropin Market, By Technology, 2021 Vs 2030, %
  • FIG. 13 U.S. Human Chorionic Gonadotropin Market (US$ Million), 2020 - 2030
  • FIG. 14 Canada Human Chorionic Gonadotropin Market (US$ Million), 2020 - 2030
  • FIG. 15 Rest of North America Human Chorionic Gonadotropin Market (US$ Million), 2020 - 2030
  • FIG. 16 UK Human Chorionic Gonadotropin Market (US$ Million), 2020 - 2030
  • FIG. 17 Germany Human Chorionic Gonadotropin Market (US$ Million), 2020 - 2030
  • FIG. 18 Spain Human Chorionic Gonadotropin Market (US$ Million), 2020 - 2030
  • FIG. 19 Italy Human Chorionic Gonadotropin Market (US$ Million), 2020 - 2030
  • FIG. 20 France Human Chorionic Gonadotropin Market (US$ Million), 2020 - 2030
  • FIG. 21 Rest of Europe Human Chorionic Gonadotropin Market (US$ Million), 2020 - 2030
  • FIG. 22 China Human Chorionic Gonadotropin Market (US$ Million), 2020 - 2030
  • FIG. 23 Japan Human Chorionic Gonadotropin Market (US$ Million), 2020 - 2030
  • FIG. 24 India Human Chorionic Gonadotropin Market (US$ Million), 2020 - 2030
  • FIG. 25 Australia Human Chorionic Gonadotropin Market (US$ Million), 2020 - 2030
  • FIG. 26 South Korea Human Chorionic Gonadotropin Market (US$ Million), 2020 - 2030
  • FIG. 27 Rest of Asia Human Chorionic Gonadotropin Market (US$ Million), 2020 - 2030
  • FIG. 28 Brazil Human Chorionic Gonadotropin Market (US$ Million), 2020 - 2030
  • FIG. 29 Mexico Human Chorionic Gonadotropin Market (US$ Million), 2020 - 2030
  • FIG. 30 Rest of Latin America Human Chorionic Gonadotropin Market (US$ Million), 2020 - 2030
  • FIG. 31 GCC Human Chorionic Gonadotropin Market (US$ Million), 2020 - 2030
  • FIG. 32 Africa Human Chorionic Gonadotropin Market (US$ Million), 2020 - 2030
  • FIG. 33 Rest of Middle East and Africa Human Chorionic Gonadotropin Market (US$ Million), 2020 - 2030